NLS Pharmaceutics Ltd (NLSP)       0.5305  -0.06 (-9.66%)

0.5305  -0.06 (-9.66%)

CH0523961370 - Common Stock - After market: 0.531 +0 (+0.09%)

News Image
24 days ago - NLS Pharmaceutics AG

NLS Pharmaceutics Announces Receipt of NASDAQ Minimum Bid Price Notification

ZURICH, SWITZERLAND / ACCESSWIRE / June 10, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it has received a written notice (the "Notice") from Nasdaq Stock Market LLC, indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a period of 180 calendar days to regain compliance with the minimum bid price requirement. The Notice has no immediate effect on the Company's Nasdaq listing or the trading of its common shares, and during the grace period, as may be extended, NLS's common shares will continue to trade on the Nasdaq Capital Market under the symbol "NLSP".

News Image
a month ago - NLS Pharmaceutics AG

NLS Pharmaceutics Appoints Chad C. Hellmann as Chief Financial Officer

ZURICH, SWITZERLAND / ACCESSWIRE / June 6, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Chad C. Hellmann has been appointed to the position of Chief Financial Officer ("CFO"). Serving most recently as CFO and co-portfolio manager of Arcus Ventures, Mr. Hellmann brings to NLS significant expertise in developing and implementing operational strategies and capital markets solutions for life sciences companies. NLS also announces that Subhasis Roy has resigned as Interim CFO and will remain a consultant to the Company through June 30, 2022 to assist with the CFO transition. NLS expresses its deep appreciation to Mr. Roy for his many contributions to the Company.

News Image
a month ago - NLS Pharmaceutics AG

NLS Pharmaceutics Announces Over Enrollment in its Phase 2a Clinical Trial Evaluating Quilience(R) for the Treatment of Narcolepsy

ZURICH, SWITZERLAND / ACCESSWIRE / June 2, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that its Phase 2a clinical trial for Quilience in the treatment of narcolepsy is now fully enrolled, with top-line results anticipated to be presented at a symposium during the European Sleep Research Society Congress (ESRS), being held September 27-30, 2022 in Athens, Greece. Additionally, the Company reports that enrollment and ongoing patient dosing in its OLE study for Quilience monotherapy continue to exhibit favorable trends.

News Image
2 months ago - NLS Pharmaceutics AG

NLS Pharmaceutics Achieves 90% Enrollment Milestone in Quilience(R) Phase 2a Clinical Trial for Patients with Narcolepsy

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

News Image
2 months ago - NLS Pharmaceutics AG

NLS Pharmaceutics Ltd. Announces Closing of US$4.4 Million Registered Direct Offering

ZURICH, SWITZERLAND / ACCESSWIRE / April 26, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorder, today announced the closing of its previously announced registered direct offering with health-care focused institutional investors

News Image
2 months ago - NLS Pharmaceutics AG

NLS Pharmaceutics to Participate in the B. Riley Annual Neuro & Ophthalmology Investor Conference

ZURICH, SWITZERLAND / ACCESSWIRE / April 22, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Alex Zwyer, CEO and Co-Founder, will participate in a fireside chat at the B. Riley Annual Neuro & Ophthalmology Investor

News Image
3 months ago - NLS Pharmaceutics AG

NLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

ZURICH, SWITZERLAND / ACCESSWIRE / April 13, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorder, today announced that it has entered into definitive agreements with health-care focused institutional investors alongside participation

News Image
3 months ago - NLS Pharmaceutics AG

NLS Pharmaceutics Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements

ZURICH, SWITZERLAND / ACCESSWIRE / April1, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it has received a letter from the Listing Qualifications staff of The Nasdaq Stock Market ("Nasdaq") notifying the Company

News Image
3 months ago - NLS Pharmaceutics AG

NLS Pharmaceutics Retains LifeSci Partners As Financial Advisor To Evaluate Strategic Partnering Initiatives

ZURICH, SWITZERLAND / ACCESSWIRE / March 31, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it has retained LifeSci Partners as financial advisor to assist the Company in evaluating a variety of strategic partnering

News Image
3 months ago - NLS Pharmaceutics AG

NLS Pharmaceutics Announces Early Access Program (EAP) Allowing Patients with Idiopathic Hypersomnia to Receive Treatment with Mazindol ER

- Named Patient Program (NPP) enables physicians to prescribe the Company's novel Mazindol Extended-Release (ER) formulation to patients who have failed approved therapies - Product sales through the NPP are expected to be revenue-generating, with patient access anticipated to begin in Q2 2022 ZURICH, SWITZERLAND / ACCESSWIRE / March 28, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage

News Image
3 months ago - NLS Pharmaceutics AG

NLS Pharmaceutics to Participate in Maxim Group 2022 Virtual Growth Conference

ZURICH, SWITZERLAND / ACCESSWIRE / March 25, 2022 - NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Alex Zwyer, CEO and Co-Founder, will participate in a fireside chat at the Maxim Group 2022 Virtual Growth Conference, being held

News Image
4 months ago - NLS Pharmaceutics AG

NLS Pharmaceutics Announces Positive Interim Top-Line Data for Quilience(R) (Mazindol ER) in Patients with Narcolepsy

- Clinically meaningful results with Mazindol ER exhibiting a 39% reduction in ESS from baseline (-4.3 points placebo-adjusted); confirms statistical powering of the ongoing Phase 2a trial - Safety and tolerability data consistent with prior mazindol clinical trials, no reported SAEs - 82% of patients that completed the randomized trial to date have rolled over into the open label extension (OLE) study - Majority of patients that enrolled in

News Image
4 months ago - NLS Pharmaceutics AG

NLS Pharmaceutics to Participate in the SACHS 15th Annual European Life Sciences Virtual CEO Forum and a Fireside Chat with Maxim Analyst in March

ZURICH, SWITZERLAND / ACCESSWIRE / February 25, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Alex Zwyer, Chief Executive Officer and Co-Founder, will be available for one-on-one meetings with conference attendees

News Image
5 months ago - NLS Pharmaceutics AG

NLS Pharmaceutics to Participate in 2022 BIO CEO & Investor Conference

ZURICH, SWITZERLAND / ACCESSWIRE / February 11, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Alex Zwyer, Chief Executive Officer and Co-Founder, will be available for one-on-one meetings with conference attendees.

News Image
5 months ago - NLS Pharmaceutics AG

NLS Pharmaceutics to Present Interim Top-Line Data for Quilience(R) (Mazindol ER) in Patients with Narcolepsy at the World Sleep Congress in March 2022

- Phase 2a trial meets enrollment target for interim analysis and is now more than 50% enrolled - 21 clinical sites in the United States actively enrolling patients - Nearly 90% of patients completing the trial have opted into the Open Label Extension study ZURICH, SWITZERLAND / ACCESSWIRE / February 7, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the

News Image
6 months ago - NLS Pharmaceutics AG

NLS Pharmaceutics Invites Patients, Caregivers and Other Interested Parties to Attend International Narcolepsy Webinar

ZURICH, SWITZERLAND / ACCESSWIRE / January 12, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Wake Up Narcolepsy, a leading patient advocacy organization dedicated to serving the narcolepsy community, will host an online

News Image
6 months ago - PennyStocks.com

3 Penny Stocks to Watch in the Second Week of January

Here are three penny stocks to add to your watchlist for next week

News Image
6 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning, trader! Let's start off the day right with a look into some of the biggest pre-market stock movers for Thursday!

News Image
6 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning, trader! It's time for another busy day of trading with a look at the biggest pre-market stock movers for Wednesday!

News Image
6 months ago - NLS Pharmaceutics AG

NLS Pharmaceutics Announces Patent Issuance in the United States for its Mazindol Extended-Release Formulation

- Key patent now granted in major markets including the U.S., Europe, Canada & South Korea - Patent claims cover use of the Company's lead product candidate, Quilience® (mazindol ER) in both attention deficit hyperactivity disorder (ADHD) & narcolepsy STANS, SWITZERLAND / ACCESSWIRE / January 4, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused

News Image
7 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Welcome back, trader! We're starting off another busy week with a look at the biggest pre-market stock movers for Monday!

News Image
7 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning, trader! We're gearing up for another busy day of trading with the biggest pre-market stock movers for Thursday!